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Abstract
Ewing sarcoma is the second most common bone malignancy in children and young adults. It is driven by oncogenic fusion
proteins (i.e. EWS/FLI1) acting as aberrant transcription factors that upregulate and downregulate target genes, leading to
cellular transformation. Thus, identificating these target genes and understanding their contribution to Ewing sarcoma
tumorigenesis are key for the development of new therapeutic strategies. In this study we show that lysyl oxidase (LOX), an
enzyme involved in maintaining structural integrity of the extracellular matrix, is downregulated by the EWS/FLI1
oncoprotein and in consequence it is not expressed in Ewing sarcoma cells and primary tumors. Using a doxycycline
inducible system to restore LOX expression in an Ewing sarcoma derived cell line, we showed that LOX displays tumor
suppressor activities. Interestingly, we showed that the tumor suppressor activity resides in the propeptide domain of LOX
(LOX-PP), an N-terminal domain produced by proteolytic cleavage during the physiological processing of LOX. Expression of
LOX-PP reduced cell proliferation, cell migration, anchorage-independent growth in soft agar and formation of tumors in
immunodeficient mice. By contrast, the C-terminal domain of LOX, which contains the enzymatic activity, had the opposite
effects, corroborating that the tumor suppressor activity of LOX is mediated exclusively by its propeptide domain. Finally,
we showed that LOX-PP inhibits ERK/MAPK signalling pathway, and that many pathways involved in cell cycle progression
were significantly deregulated by LOX-PP, providing a mechanistic explanation to the cell proliferation inhibition observed
upon LOX-PP expression. In summary, our observations indicate that deregulation of the LOX gene participates in Ewing
sarcoma development and identify LOX-PP as a new therapeutic target for one of the most aggressive paediatric
malignancies. These findings suggest that therapeutic strategies based on the administration of LOX propeptide or
functional analogues could be useful for the treatment of this devastating paediatric cancer.
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Introduction
Ewing sarcoma is an aggressive neoplasm that mainly affects
child and young adults in the first and second decade of life. It
mainly occurs in bones although a small percentage of these
tumors also arise in soft tissues. Even though the overall survival
rates have significantly risen in the last decades, an elevated
percentage of these tumors are refractory to conventional chemo-
and radiotherapy, making more necessary the development of new
therapeutic strategies (reviewed in [1]). The development of new
therapeutic strategies will only be possible through a better
knowledge of the molecular mechanisms that govern the process of
malignant transformation in these tumors.
The molecular hallmark of Ewing sarcoma is the presence of
chromosomal translocations that generate fusion proteins with
aberrant transcriptional activities. The most common of these
translocations, observed in approximately 85% of the cases, is
t(11;22) that fuse the EWS gene to the FLI1 transcription factor
resulting in the EWS/FLI1 fusion protein. Other fusion proteins
involving the EWS gene (and less frequently other related genes)
and other transcription factors of the ets family have been
described in the remainder cases. During the last years, important
efforts have been made to identify gene targets of the EWS/FLI1
oncoprotein in Ewing sarcoma cells (reviewed in [2–6]). Many of
these target genes have been shown to regulate cell proliferation,
invasiveness, metastasis or responsiveness to oxidative stress in
Ewing sarcoma cells (reviews above and [7])
Cellular models engineered to silence EWS/FLI1 expression by
means of RNA interference have been very useful for the
identification and characterization of relevant downstream targets
of EWS/FLI1 [8–19]. Particularly, inducible shRNA models have
been especially advantageous, allowing us to identify some of the
genes that participate in the pathogenesis of Ewing tumors, such as
cholecystokinin, DKK1 and the orphan nuclear receptor DAX1/
NR0B1 [8,9,20].
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EWS/FLI1 induced genes are expected to work functionally like
oncogenes, while EWS/FLI1 repressed genes are expected to act
functionally like tumor supressor genes. It is interesting that
although EWS/FLI1 was shown to act as a potent transcriptional
activator [21,22], a significant proportion of EWS/FLI1 target
genes are downregulated by this oncogenic protein [11,23,24].
The mechanism of this specific gene repression is only partially
understood, and probably involves direct repression [11,23–25],
upregulation of transcriptional repressors [26] and epigenetic
mechanisms [15]. In addition, EWS/FLI1 has been also shown to
regulate the expression of microRNAs that in turn are available to
regulate the expression of other genes involved Ewing sarcoma
tumorigenesis [27,28].
Analysis of our gene expression profile dataset in the Ewing
sarcoma cell line A673 upon EWS/FLI1 knockdown showed that
one of the most strongly downregulated genes by EWS/FLI1
codes for the enzyme lysyl oxidase (LOX). LOX is the major
member of a family of lysyl oxidases (that include LOX and the
LOX-like proteins LOXL1 to LOXL4) that share the enzyme
catalytic domain (reviewed in [29–32]). LOX is synthesized as a
50-KDa inactive pre-proenzyme which is secreted into the
extracellular environment and then processed by proteolytic
cleavage to a functional 32-KDa LOX enzyme (LOXenz) and
an 18-KDa propeptide (LOX-PP). It is well characterized that the
functional mature enzyme catalyses lysine-derived covalent cross-
links required for normal structural integrity of the extracellular
matrix and a huge amount of information on this function, both in
physiological and pathological situations, has been accumulated
during several decades (reviewed in [29–32]). The role of the
propeptide has been, however, much less studied, although recent
reports suggest that LOX propeptide acts as a tumor suppressor in
several contexts [33–35]. Currently, no data are available about
the possible contribution of LOX repression to the malignant
phenotype of Ewing sarcoma.
In this work, we show that EWS/FLI1 downregulates LOX
expression and that, remarkably, LOX propeptide exhibits tumor
suppressor activities in Ewing tumor cells. Ectopic expression of
LOX propeptide in an Ewing sarcoma cell line reduced cell
proliferation, cell migration, anchorage independent growth and
tumor growth in vivo. These findings suggest that therapeutic
strategies based in the administration of LOX propeptide or
functional analogues could be useful for the treatment of this
devastating paediatric cancer.
Results
During the last years we have used an inducible model of EWS/
FLI1 knockdown in combination with whole gene expression
analysis to identify and characterize EWS/FLI1 target genes
relevant for Ewing sarcoma tumorigenesis ([8,9,36]). Review of
these datasets (GEO accession number GSE36007) indicated that
one of the genes that showed a more intense and consistent
downregulation by EWS/FLI1 was the enzyme lysyl oxidase
(LOX, Protein-lysine 6-oxidase EC 1.4.3.13). Consequently, we
decided to study the regulation of LOX by EWS/FLI1 and the
functional implications of this downregulation.
To confirm microarray data, we used A673/TR/shEF Ewing
cells, which in response to doxycycline express a specific shRNA
directed against EWS/FLI1 mRNA, subsequently reducing the
levels of EWS/FLI1 mRNA and protein [8,9]. We isolated RNA
from A673/TR/shEF cells incubated in absence or in presence of
doxycycline and performed real time quantitative RT-PCR (qRT-
PCR) analysis. Time-course experiments confirmed that LOX is a
gene downregulated by EWS/FLI1, since LOX mRNA levels
were significantly upregulated upon EWS/FLI1 knockdown in the
A673 Ewing sarcoma cell line (Figure 1A). As shown in figure 1B,
LOX protein was nearly undetectable in A673/TR/shEF cells in
basal conditions. However, EWS/FLI1 knockdown produced a
dramatic increase in LOX protein levels confirming that EWS/
FLI1 downregulates LOX expression in these cells. To analyse if
LOX expression downregulation is a common feature of Ewing
cells, we analysed by western-blot the levels of LOX protein in a
panel of Ewing derived cell lines (n = 8) harbouring different
oncogenic fusion proteins. As shown in Figure 1C, LOX
expression in these Ewing sarcoma cell lines was nearly
undetectable, while high LOX expression was observed in IMR-
90 normal fibroblasts, which were used here as a positive control of
LOX expression. We then analysed the levels of LOX mRNA in
Ewing primary tumors using qRT-PCR and compared them with
the levels observed in the positive control IMR-90. Figure 1D
shows that LOX mRNA levels are low in Ewing primary tumors
compared to those observed in IMR90 cells. In addition, we
searched public expression datasets in order to analyse the relative
expression of LOX in Ewing sarcoma in relation to other tumor
types. As shown in supplementary figure S1, LOX expression was
low in Ewing sarcoma tumors, compared to other neoplasms.
Next, we analysed if epigenetic mechanisms, known to repress
gene expression, could be involved in the negative regulation of
LOX expression observed in Ewing sarcoma cells. We first studied
the effect of Vorinostat (SAHA), a class I/II histone deacetylase
inhibitor approved for clinical use in cancer patients ([37]). A673
cells were incubated in presence or absence of SAHA for 24 hours
and LOX mRNA levels were quantified by qRT-PCR. As shown
in Figure 2A, incubation of A673 Ewing cells with SAHA
produced a 5-fold increase in LOX mRNA levels. Following, we
analysed the effect of 5-aza-cytidine (5-aza), a potent inhibitor of
DNA methyltransferase 1 (DNMT1) that induces demethylation
and reactivation of silenced genes [38] on LOX expression. As
shown in figure 2B, incubation of A673 Ewing cells with 5-aza
during 72 hours produced a 10-fold increase in LOX mRNA
levels. These results suggest that both histone acetylation status
and DNA methylation could be involved in the negative regulation
of LOX expression in A673 cells.
The fact that EWS/FLI1 downregulates LOX in the A673
Ewing sarcoma cell line and that low levels of LOX are a common
feature of Ewing sarcoma cells and tumors, suggest that LOX
could act as a tumor suppressor in Ewing tumors. In this case,
LOX re-expression should antagonize, at least in part, the
transforming properties of EWS/FLI1 in Ewing tumor cells. To
confirm this hypothesis, we performed functional studies to
determine the effect of LOX re-expression in the A673 Ewing
cell line model.
As previously mentioned, LOX is synthesized as a 50-KDa
inactive proenzyme (preLOX) which is secreted to the extracel-
lular environment. There, it is processed by proteolytic cleavage to
a functional 32-KDa LOX enzyme (LOXenz) and an 18-KDa
propeptide (LOX-PP). We thus genetically modified the A673
Ewing sarcoma cell line to express LOX proenzyme (A673/TR/
preLOX, aminoacides 1-415), its catalytic domain (A673/TR/
LOXenz, aminoacides 166-415) and the LOX propeptide (A673/
TR/LOX-PP, aminoacides 1-179) in an attempt to characterize
the specific contribution of full-length LOX and of each one of the
LOX-derived fragments to Ewing sarcoma tumorigenesis
(Figure 3A). We have used a doxycycline-inducible system to
express these proteins because, in our opinion, it has significant
advantages to analyse genes that may be acting as tumor
suppressors since constitutive expression of these genes is expected
to produce deleterious effects on transformed cells.
LOX-PP Supresses Ewing Sarcoma Tumorigenesis
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As shown in Figure 3B, preLOX, LOXenz and LOX-PP
mRNAs were induced upon doxycycline stimulation in the A673/
TR/preLOX, A673/TR/LOXenz and A673/TR/LOX-PP Ew-
ing cells respectively. In all cases, levels of EWS/FLI1 mRNA
were not altered by doxycycline stimulation, making this an
excellent model to analyse the effect of the induction of the
different LOX proteins and their contribution to Ewing patho-
genesis. Western-blot analyses were used to confirm the expression
of the corresponding proteins: preLOX and LOXenz were
detected by western-blot in whole cell extracts as proteins with
molecular weights slightly larger than expected, because of the V5
N-terminal tag sequence that was fused to the proteins to facilitate
their detection with an anti-V5 specific antibody (Figure 3C). In
contrast, LOX-PP was not detected in whole cell extracts
(Figure 3C), suggesting that it was rapidly and efficiently secreted
to the culture media. To confirm this, we used immunoprecipi-
tation to analyse the culture media of A673/TR/LOX-PP cells
incubated in absence or in presence of doxycycline. As shown in
figure 3D, LOX-PP was detected as a diffuse band of approxi-
mately 30 KDa in culture media of A673/TR/LOX-PP cells
stimulated with doxycycline, suggesting that this protein was
strongly glycosylated, as previously reported [39–41]. In order to
demonstrate that this diffuse band corresponds to secreted LOX-
PP highly glycosylated, we treated a fraction of the immunopre-
cipitated LOX-PP with the enzyme N-glycosidase (PNGase F) to
remove N-linked oligosaccharides. After N-glycosidase treatment
(Figure 3E), LOX-PP migrated as a single band of approximately
18 kDa, which corresponds to its predicted size according to its
amino acid composition and demonstrates that LOX-PP produced
by A673/TR/LOX-PP cells is processed adequately. Unglycosy-
lated LOX-PP was also observed in untreated LOX-PP, although
it was present in a very low quantity, indicating that a minimal
fraction of the secreted LOX-PP was unglycosylated.
We next analyzed the effect of preLOX, LOX-PP and LOXenz
on cell proliferation. As shown in Figure 4, induction of preLOX
by doxycycline in A673/TR/preLOX cells resulted in a significant
Figure 1. LOX mRNA and protein are downregulated by EWS/FLI1 in the A673 Ewing sarcoma cell line. A) A673/TR/shEF cells were
stimulated by different periods of time with doxycycline (DOX, 1 mg/ml) to induce the expression of an EWS/FLI1-specific shRNA. The levels of LOX,
EWS/FLI1 and TBP (reference gene) mRNA were quantified by multiplex real time qRT-PCR. For each time point, LOX and EWS/FLI1 mRNA levels were
normalized to that of TBP and referred to unstimulated cells. The figure shows the data (mean6SD) of one out of two independent experiments done
in triplicate with equivalent results. B) LOX protein levels were also determined by western-blot in the A673/TR/shEF cells stimulated with
doxycycline. The same blot was stripped and successively incubated with anti-FLI1 antibody to assess the expression of EWS/FLI1 and with anti-a-
tubulin as a control for loading and transferring. LOX mRNA and protein levels were strongly downregulated by EWS/FLI1. C) LOX protein levels were
determined by western-blot in 8 Ewing derived cell lines and in normal fibroblasts IMR-90, used here as a positive control of LOX expression. A673/
TR/shEF cells stimulated with doxycycline for 48 hours were also included. The type of EWS/FLI1 (EF; EWS exon/FLI1 exon) and EWS/ERG fusion (EE;
EWS exon/ERG exon) present in each Ewing cell line are indicated. LOX protein expression was nearly undetectable in Ewing derived cell lines. D) LOX
mRNA levels were quantified by qRT-PCR in a set of Ewing’s primary tumors (n = 21). Normal fibroblasts IMR-90 are used as a positive control. mRNA
levels were normalized to that of TBP (mean6SD). LOX mRNA levels observed in Ewing tumors were very low compared to those observed in the
control fibroblast cell line IMR-90.
doi:10.1371/journal.pone.0066281.g001
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reduction (30%) in the number of population doubling accumu-
lated during 25 days. This inhibitory effect on cell proliferation
was clearly more pronounced (45%) when LOX-PP was induced
in A673/TR/LOX-PP cells. Interestingly, the effect of LOXenz
on cell proliferation was the opposite, with an increase in the
number of population doubling upon LOXenz induction. No
effect on cell proliferation was observed in A673 cells carrying the
empty vector, both in absence and in presence of doxycycline. To
confirm these effects on cell proliferation, we performed additional
experiments using an available commercial kit designed to
quantify viable cells (Cell-titer fluor cell viability assay). As shown
in Figure 4B, induction of preLOX in two independent clones of
A673/TR/preLOX cells produced a reduction (about 20%) in the
number of viable cells. This inhibitory effect on cell number
became again more pronounced (about 50%) when LOX-PP was
induced in A673/TR/LOX-PP cells. By contrast, the induction of
LOXenz resulted in an increase in the number of viable cells.
Taken together, these results demonstrate that preLOX inhibits
cell proliferation in Ewing cell lines and more interestingly, that
this inhibitory effect on cell proliferation resides in the LOX
propeptide. To additionally characterize these findings, we used
the irreversible antagonist of lysyl oxidase activity b-amino-
propionitrile (b-APN) [33]. As shown in Figure 4C, treatment
with b-APN increased the inhibitory effect of preLOX on cell
proliferation. Since preLOX expression results in the production
of both the propeptide domain LOX-PP and the catalytic domain
LOXenz, this result indicates that lysyl oxidase activity (which
resides in LOXenz) is partially counteracting the cell proliferation
inhibition mediated by LOX-PP. Furthermore, b-APN totally
blocked the stimulatory effect of LOXenz on cell proliferation,
demonstrating that this effect is entirely dependent on the lysyl
oxidase catalytic activity. In concordance with this, b-APN had no
effect on the cell proliferation inhibition observed upon LOX-PP
induction. These results confirm that the inhibitory effect of LOX
on cell proliferation resides in the LOX propeptide. Subsequently,
we analyzed the effect of an exogenous source of LOX-PP on cell
proliferation. For this purpose, we incubated A673 cells with
LOX-PP rich media, obtained from conditioned media of A673/
TR/LOX-PP cells stimulated with doxycycline during 72 hours.
Control media, without LOX-PP, was obtained in parallel from
the same cells incubated in absence of doxycycline for 72 hours.
As shown in figure 4D, LOX-PP enriched media, reduced by 50%
the cell number in A673 Ewing cells.
Following, we analysed the effect of preLOX, LOX-PP and
LOXenz on cell migration and the ability to grow in an
anchorage-independent manner. In Figure 5A are shown the
effects of preLOX, LOX-PP and LOXenz on cell migration
through porous membranes in response to serum. Induction of
preLOX with doxycycline in the A673/TR/preLOX cells did not
produce a significant difference in the number of cells migrating
through the membrane. However, the induction of LOX-PP in
A673/TR/LOX-PP cells decreased cell migration through the
porous membranes by 35%, indicating that LOX-PP is also active
in inhibiting cell migration. In this case, LOXenz also showed the
opposite effect when compared to LOX-PP. Thus, LOXenz
increased the migration of A673 cells by 25%. Afterwards, we
analysed the effect of preLOX, LOX-PP and LOXenz on the
ability of A673 cells to grow in soft agar. As shown in Figure 5B,
preLOX and LOX-PP induction decreased the number of
colonies grown in soft agar by approximately 25% and 30%,
respectively. By contrast, LOXenz increased the number of
colonies by about 50%.
Subsequently, we performed xenograft experiments to analyse
the effect of LOX-PP on tumor growth in vivo (Figure 5C). Mice
were injected subcutaneously with A673/TR/empty or A673/
TR/LOX-PP and each group of animals was split into two groups
of treatment, one of which was given doxycycline in the drinking
water to induce the expression of the corresponding protein. As
expected, animals injected with A673/TR/empty cells produced
tumors both in the absence and in the presence of doxycycline in
the drinking water. Animals injected with A673/TR/LOX-PP
cells but not treated with doxycycline also developed tumors at the
same rate as the animals injected with the A673/TR/empty
control cells. However, we did not detect visible tumors in the
animals injected with A673/TR/LOX-PP cells and treated with
doxycycline, and thus expressing LOX-PP. Taken all together
these results indicate that LOX-PP is a suppressor of Ewing
sarcoma tumorigenesis.
Following, in an attempt to identify the pathways involved in
the antiproliferative effect of LOX-PP we analysed by western-blot
the status of the PI3K/AKT and ERK/MAPK pathways. As
shown in Figure 6, induction of LOX-PP with doxycycline had no
effect on the levels of activated Akt (P-Ser 473). By contrast, LOX-
PP produced a marked inhibition of the levels of activated Erk (P-
Tyr 204).
Finally, we performed a gene expression microarray experiment
to identify genes and pathways specifically regulated by LOX-PP
in A673 cells (GEO accession number GSE46407). Thus, we
stimulated A673/TR/LOX-PP cells with doxycycline for
72 hours and compared its gene expression profile to that of the
control cells A673/TR/empty. In order to identify pathways
specifically affected by LOX-PP in A673 cells, we analysed the
expression data sets with GSEA (Gene Set Enrichment Analysis)
[42]. As shown in supplementary table S1, GSEA analysis
identified many gene sets/pathways from the REACTOME
curated database (www.reactome.org) that were significantly
regulated by LOX-PP (FDR,0.005). Among the 19 gene sets
Figure 2. Effect of the histone deacetylases inhibitor SAHA and
the demethylating agent 5-aza-29-deoxycytidine on LOX mRNA
levels. A) A673 cells were incubated in absence (C) or presence of
SAHA 1 mM for 24 hours and the levels of LOX and TBP (reference gene)
mRNAs quantified by multiplex real time qRT-PCR. LOX mRNA levels
were normalized to that of TBP and referred to unstimulated control (C)
cells, which were arbitrary set to 1. The figure shows the data
(mean6SD) of three independent experiments done in triplicate. The
figure shows the mean6SD of one out of two independent
experiments done in duplicate (*P,0.01 vs control). B) A673 cells were
incubated in the absence (C) or presence of 5-aza-29-deoxycytidine
1 mM for 24, 48, 72 or 96 hours and the levels of LOX and TBP (reference
gene) mRNAs quantified by qRT-PCR and analysed as above. The figure
shows the mean6SD of two independent experiments done in
duplicate (*P,0.01 vs control). Both SAHA and 5-aza-29-deoxycytidine
produce a significant increase in the levels of LOX mRNA in A673 cells.
doi:10.1371/journal.pone.0066281.g002
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Figure 3. Establishment of Ewing sarcoma cell lines expressing doxycycline-inducible preLOX, LOX-PP and LOXenz proteins. A)
Schematic representation of preLOX, LOX-PP and LOXenz cDNAs cloned in the doxycycline-inducible lentiviral vector pLenti-TO-V5-DEST. SP: signal
peptide. B) A673/TR Ewing cell line expressing high levels of the tetracycline repressor (TR) was infected with the doxycycline-inducible lentiviral
vector encoding the different LOX cDNAs and stable clones were selected. The figure shows two independent clones for each construction
stimulated with doxycycline (DOX, 1 mg/ml, 48 hours) to induce the expression of the corresponding mRNAs. preLOX, LOX-PP and LOXenz mRNAs
were detected by RT-PCR using LOX-specific (LOXF6 or LOXF9) and V5 tag-specific primers (V5R). EWS/FLI1 fusion mRNA remained unchanged upon
LOX induction. TBP (TATA-binding protein) was used as an internal housekeeping control. C) Whole protein extracts were isolated from A673/TR/
preLOX (clone 3), A673/TR/LOXenz (clone 1) and A673/TR/LOX-PP (clon 2) cells stimulated with doxycycline (DOX, 1 mg/ml, 48 hours) and analysed by
western-blot to detect the expression of preLOX, LOXenz and LOX-PP proteins, respectively, using an anti-V5 antibody. The same blot was stripped
and incubated with anti-a-tubulin as a control for loading and transferring. preLOX and LOXenz, but not LOX-PP, were detected in whole cell extracts.
D) Conditioned media derived from A673/TR/LOX-PP (clone 2) incubated with doxycycline (DOX, 1 mg/ml, 48 hours) was concentrated and
immunoprecipitated with an anti-V5 antibody to confirm the secretion of LOX-PP in the culture media. An anti-a-tubulin or no antibody were used as
negative controls. LOX-PP was detected in the culture media derived from A673/TR/LOX-PP stimulated with doxycycline indicating that LOX-PP was
efficiently processed and secreted. E) Conditioned media derived from A673/TR/LOX-PP cells stimulated with doxycycline was immunoprecipitated
and untreated or treated with the enzyme peptide-N-glycosidase (PNGase F). Glycosylated LOX-PP was observed as a diffused band of approximately
30 KDa in the untreated sample, that became a defined band of 18 KDa upon deglycosylation treatment. A673/TR/LOX-PP cells without doxycycline
were used as a negative control of LOX-PP production.
doi:10.1371/journal.pone.0066281.g003
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Figure 4. Induction of preLOX and LOX-PP inhibits cell proliferation in A673 Ewing sarcoma cells. A) A polyclonal population and a
representative clone of A673/TR/empty (control cells), A673/TR/preLOX, A673/TR/LOX-PP and A673/TR/LOXenz cells were maintained during 25 days in
standard culture medium or in culture medium containing doxycycline (DOX, 1 mg/ml) to induce the expression of the corresponding proteins.
Cumulative number of population doubling were determined by counting cells at different periods of time and plotted versus time. B) Representative
clones of A673/TR/empty, A673/TR/preLOX, A673/TR/LOX-PP and A673/TR/LOXenz cells were incubated in the absence or in the presence of
doxycycline (DOX, 1 mg/ml) for 5 days to induce the corresponding proteins and cell growth quantified by CellTiter-Fluor assay. The figure shows the
mean6SD of one out of three independent experiments done in triplicate with similar results. Data are shown as percentage versus unstimulated cells,
which were arbitrarily set to 100 (*P,0.05, **P,0.005 versus unstimulated cells). C) A673/TR/empty, A673/TR/preLOX, A673/TR/LOX-PP and A673/TR/
LOXenz cells were incubated in the absence or in the presence of doxycycline (DOX, 1 mg/ml) and in the absence or in the presence of the irreversible
antagonist of lysyl oxidase activity b-aminopropionitrile (b-APN, 500 mM). The figure shows the mean6SD of one out of two independent experiments
done in triplicate with equivalent results. Data are shown as percentage versus unstimulated cells, which were arbitrarily set to 100 (*P,0.05, **P,0.005,
ns: not significant). D) A673 cells were incubated during 72 hours with conditioned media derived from A673/TR/LOX-PP cells cultured in absence of
doxycycline (control) or conditioned media derived from the same cells cultured in presence of doxycycline to induce the expression of LOX-PP (LOX-PP
rich media). The figure shows the mean6SD of two independent experiments done in triplicate. Data are shown as percentage versus cells incubated
with control media, which were arbitrarily set to 100 (*P,0.05). LOX-PP rich media significantly reduced cell proliferation of A673 cells.
doi:10.1371/journal.pone.0066281.g004
LOX-PP Supresses Ewing Sarcoma Tumorigenesis
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displaying a FDR,0.005, 14 were related to DNA synthesis and
replication and cell cycle regulation (Supplementary table S1 and
figure S2), indicating that LOX-PP was clearly affecting cell
proliferation. LOX-PP induction also affected other pathways
related to cell metabolism (3 gene sets) and extracellular matrix
organization (2 gene sets). Taken together, these data suggest that
LOX-PP is affecting cell proliferation, first, by producing a
significant inhibition of the ERK/MAPK pathway, and subse-
quently, by affecting pathways involved in cell cycle progression.
Discussion
Ewing sarcoma is a highly aggressive paediatric cancer that in
an elevated percentage of cases is refractory to standard treatments
(reviewed in [1]). Therefore, studies designed to identify new
therapeutic targets in Ewing tumors are eagerly needed. Ewing
sarcoma is characterized by chromosomal translocations that lead
to the expression of chimeric transcription factors (the most
frequent of which is the fusion protein EWS/FLI1), which are
thought to be the responsible for tumor initiation [3–5]. Because
EWS/FLI1 (and the related fusion proteins) deregulates a large set
of target genes, identification of these genes is not only important
to increase our understanding about Ewing tumorigenesis, but
more importantly to identify new targets that could be pharma-
cologically modulated.
Whole genome expression analysis has been especially useful to
identify EWS/FLI1 target genes and to provide a relevant amount
of information about genes and pathways involved in Ewing
tumorigenesis [43]. However, in order to identify new valuable
therapeutic targets, functional analysis should be performed ‘‘gene
to gene’’ to establish the individual contribution of each gene to
the malignant phenotype. With this in mind, in this work we
analysed the contribution of lysyl oxidase (LOX), a EWS/FLI1
downregulated gene target, to Ewing tumorigenesis.
Microarray studies and real time quantitative RT-PCR
demonstrated that LOX mRNA was downregulated by the
EWS/FLI1 oncoprotein in the A673 Ewing sarcoma cell line.
Figure 5. LOX-PP induction inhibits growth in soft agar, cell migration and tumor growth in vivo. A) A673/TR/empty, A673/TR/preLOX,
A673/TR/LOX-PP and A673/TR/LOXenz cells were grown in soft agar in the absence or in the presence of doxycycline (DOX, 1 mg/ml)) for 25 days.
Culture dishes were then photographed and colony number was calculated. The figure shows the mean6SEM of three independent experiments
done in triplicate. Data are shown as percentage versus unstimulated cells, which were arbitrarily set to 100 (*P,0.05, versus unstimulated cells). B)
Two representative clones of A673/TR/empty, A673/TR/preLOX, A673/TR/LOX-PP and A673/TR/LOXenz cells were incubated in the absence or in the
presence of doxycycline (DOX, 1 mg/ml) during 48 hours to induce the expression of the corresponding proteins. Afterwards, cells were placed in the
upper compartment of a transwell and allowed to migrate through the membrane in response to serum. Migrating cells were quantified by crystal
violet staining. The figure shows the mean6SEM of one experiment done in triplicate. Data are shown as percentage versus unstimulated cells, which
were arbitrarily set to 100 (*P,0.05, versus unstimulated cells). C) Nude mice were injected with A673/TR/empty clone 1 (n = 7) or A673/TR/LOX-PP
clone 2 (n = 8) cells and split in two groups, one of which was given doxycycline (DOX, 1 mg/ml) in the drinking water to induce the expression of the
corresponding protein. The figure shows the evolution of tumor volume (mean6SEM of 3–4 animals per group) versus time.
doi:10.1371/journal.pone.0066281.g005
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Our results are consistent with other previously reported data, in
which EWS/FLI1 was also shown to downregulate LOX
expression in A673 and other Ewing cell lines (i.e. EWS502 and
TC-71) [11,17,18,44]. In agreement with this, we observed no
expression (or nearly undetectable) of LOX protein in eight
different Ewing cell lines. In addition, LOX mRNA levels were
also low in a series of Ewing primary tumors, which was also
confirmed searching public available datasets. Loss of LOX
expression has been reported in a variety of human cancers. More
than two decades ago, Kuivaniemi et al. [45] observed deficient
LOX production in a variety of malignant transformed cells, such
as HT-1080 (fibrosarcoma), A-204 (rhabdomyosarcoma) or G-361
(melanoma). More recently, reduced LOX expression has been
reported to occur in lung and pancreatic cancer [46,47] and
during malignant progression of prostate and colorectal cancers
[48,49]. Therefore, at least in some types of tumors, LOX
expression correlates negatively with malignant transformation.
Our results suggest that epigenetic mechanisms could be
involved in the downregulation of LOX mRNA in A673 Ewing
cells. In this sense, both the histone deacetylase inhibitor SAHA
and the demethylating agent 5-aza-citidine restored, at least
partially, LOX expression in A673 cells. It is difficult to assess the
quantitative contribution of these mechanisms to LOX repression,
because of the elevated toxicity of these agents, in particular
SAHA, but our results indicate that both could be involved. While
we were doing this work, Lessnick’s lab described that EWS/FLI1
oncoprotein was directly involved in the repression of LOX
promoter [25]. Interestingly, the repression of LOX promoter was
dependent on the interaction of EWS/FLI1 with the NuRD
repressor complex. In concordance with this, Sankar et al, showed
that LOX mRNA levels increased upon incubation of A673 cells
with SAHA, in agreement with our results. In addition, we also
showed that DNA methylation can be involved in the repression of
LOX gene in A673 cells, although we did not demonstrate if this
was an indirect or a direct mechanism.
One of the most interesting findings of our work is the
demonstration that lysyl oxidase and particularly, the lysyl oxidase
propeptide (LOX-PP) is a suppressor of Ewing sarcoma tumor-
igenesis. Expression of LOX propeptide decreased cell prolifera-
tion, migration, colony formation in soft agar and growth of
tumors in vivo. In addition, conditioned media containing high
levels of LOX-PP impaired cell proliferation in A673 Ewing cells.
By contrast, expression of the LOX domain containing the lysyl
oxidase activity (namely here LOXenz) showed the opposite
effects. Interestingly, when full-length LOX protein (preLOX) was
expressed in Ewing tumor cells, the inhibitory effect of LOX-PP
on cell proliferation was dominant on the stimulatory effect
mediated by LOXenz. Thus, preLOX expression produced a net
inhibitory effect on cell proliferation, which could explain why
LOX downregulation is advantageous for Ewing tumor cells.
Taken together, our results demonstrate that LOX propeptide is a
suppressor of Ewing tumorigenesis. Although we have performed
the experiments with the prototype Ewing cell line A673, we
anticipate that LOX-PP will also affect the growth and
transforming properties of other Ewing cell lines. In this sense,
Sankar et al have shown in their recently published article that
LOX (preLOX) overexpression reduced the ability of three Ewing
cell lines (A673, TC71, TC32) to form colonies in soft agar [25].
Although in that study it was not analysed the effect of LOX
propeptide itself, these results, taken together with ours, suggest
that LOX-PP could act as an antitumor agent for the majority of
Ewing sarcoma cells.
The first evidence about the tumor suppressor activity of LOX
came from studies addressed to identify the genes involved in the
IFN-c mediated-reversion of ras-transformed malignant cells. In
these studies, a gene called ras recision gene (rrg) was isolated and
shown to be responsible for malignant reversion [50]. In
agreement with this, increased LOX expression was also found
in spontaneous revertants of H-ras transformed rat fibroblasts [51]
while reduced LOX expression was observed in ras-transformed
cells [52]. In addition, Giampuzzi et al. reported that normal rat
kidney fibroblasts (NRK-49F) in which LOX mRNA was knocked
down by antisense lysyl oxidase showed loose attachment to the
plate and anchorage-independent growth and were highly
tumorigenic in nude mice [53]. These findings evidence a role
of LOX as a tumor suppressor, highlighting its particular role in
controlling Ras activation and growth factor dependence.
Palamakumbura et al, described for the first time that the lysyl
oxidase propeptide, but not the lysyl oxidase enzyme, was
responsible for the inhibition of ras-dependent transformation of
NIH3T3 cells as determined by effects on cell proliferation assays,
growth in soft agar and Akt-dependent induction of NF-kappaB
activity [33]. Subsequently, LOX-PP was shown to act as a tumor
suppressor in several cancer cells. For example, LOX-PP reverts
the invasive phenotype of breast cancer cells [34], inhibits the
transformed phenotype of lung and pancreatic cancer cells [35],
interferes with FAK activation in breast cancer cells [54] and
inhibits prostate cancer cell growth by targeting FGF-2 cell
binding and signalling [55].
The mechanism through LOX-PP act as a tumor suppressor
begins now to be only partially understood. LOX-PP has been
shown to impair both PI3K/Akt and ERK signalling pathways.
Thus, ectopic pre-LOX and LOX-PP expression in H1299 lung
cancer and PANC-1 pancreatic cancer cells inhibited growth in
soft agar and migration and reduced activation of ERK and Akt,
with LOX-PP showing substantially higher activity [35]. In MIA
PaCa-2 (a pancreatic cancer cell), LOX-PP attenuated the ERK
and Akt activities and decreased the levels of the NF-Kb p65 and
RelB subunits and cyclin D1, which are activated by RAS
signalling [56]. Palamakumbura et al. [55] showed that recombi-
nant LOX-PP protein inhibits serum-stimulated DNA synthesis
and ERK and PI3K/Akt pathways in DU 145 and PC-3
androgen-independent cell lines. Our data indicate that the
inhibition of proliferation observed upon LOX-PP expression in
Figure 6. LOX-PP interferes with ERK signalling. A673/TR/LOX-PP
cells (clone 2) were incubated in the absence or in the presence of
doxycycline (DOX, 1 mg/ml, 48 hours) and the levels of activates P-AKT
(Ser 473) and P-ERK (Tyr 204) determined by western-blot. The same
blot was stripped and successively incubated with anti-AKT, anti-ERK
and anti-a-tubulin as controls for loading and transferring.
doi:10.1371/journal.pone.0066281.g006
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A673 Ewing cells could be mainly mediated by inhibition of the
ERK pathway, while the PI3K/Akt pathway does not seem to be
involved. Therefore, specific downstream targets of LOX-PP can
depend on the cellular context. Studies carried out with gene
expression microarrays shown as well that LOX-PP modified the
expression of genes involved in specific pathways related to DNA
synthesis and replication and cell cycle regulation, indicating that
LOX-PP was clearly affecting cell proliferation. These results
suggest that LOX-PP is affecting cell proliferation, first, by
producing a significant inhibition of the ERK/MAPK pathway,
and subsequently, by affecting pathways involved in cell cycle
progression.
In summary, in this work we shown that LOX is a gene
repressed by the EWS/FLI1 oncoprotein and that its ectopic re-
expression in an Ewing cell line inhibits cell proliferation. We also
shown that this function is attributed to the LOX propeptide, an
N-terminal fragment of the LOX protein released during
processing, which in turn is able to decrease cell proliferation
and migration and to inhibit the formation of colonies in soft agar
and the growth of tumors in vivo. Our data indicates that LOX
propeptide is a tumor suppressor gene in Ewing’s tumors,
providing the bases for a rational use of LOX propeptide, derived
peptides or synthetic peptidomimetics in Ewing’s therapy.
Recently, it has been shown that LOX-PP sensitizes pancreatic
and breast cancer cells to doxorubicin-induced apoptosis, provid-
ing a rationale for LOX-PP usage in adjuvant chemotherapy [56].
Thus, in light of the broad inhibitory activities of LOX-PP shown
in this work, it will be interesting to further explore the use of
LOX-PP as a potential treatment for Ewing tumors in combina-
tion with standard chemotherapy agents.
Materials and Methods
Ethics statement
Experiments with mice were all carried out in accordance with
Institutional and European Union guidelines for the care and use
of laboratory animals. Procedures were approved by the Comité
de Ética de la Investigación y Bienestar Animal (CEIyBA) of the
Instituto de Salud Carlos III (Certificate number: PA-24_2012).
Animals were sacrificed using an overdose of sodium pentobarbital
and all efforts were made to minimize suffering.
Tumors used in this study were provided by the Departments of
Pathology and Oncology Units of several Spanish Children’s
Hospitals. A written informed consent was obtained from each
patient’s guardian. This study was approved by the Comité de
Ética de la Investigación y Bienestar Animal (CEIyBA) of the
Instituto de Salud Carlos III (Certificate number: PI- 14_2012).
Cell lines
The Ewing sarcoma cell lines A673 (CRL-1598), SK-ES-1
(HTB-86), RD-ES (HTB-166), SK-N-MC (HTB-10), and SKPN-
DW (CRL-2139) were purchased from the American Type
Culture Collection (Manassas, VA, USA). Ewing sarcoma cell
lines A4573 [57] and TTC-466 [58] were generous gifts from Dr.
S. Navarro (University of Valencia, Valencia, Spain) and Dr. T.J.
Triche (Children’s Hospital Los Angeles, Los Angeles, CA),
respectively.
Materials
Stock solution of doxycycline (Invitrogen, Grand Island, NY,
USA) were made in PBS 1x. Vorinostat (SAHA) (Sigma-Aldrich,
St. Louis, MD, USA) was dissolved in DMSO to generate a stock
solution and stored at 220uC until use. This solution was then
dissolved in sterile PBS 1X to obtain the desired concentrations. 5-
Aza-29-deoxycytidine (Sigma-Aldrich) was dissolved in DMSO
and stored at 280uC in small aliquots until use.
Establishment of Ewing̀s cell lines stably expressing
doxycycline-inducible cDNA of LOX, LOX-PP and LOXenz
The complete sequence of LOX (LOX), the propeptide region
of LOX (LOX-PP) and the mature form of LOX containing the
enzymatic activity (LOXenz) were PCR-amplified from the LOX
cDNA cloned into the vector pCMV6-XL5 (Origene, Rockville,
USA). LOX cDNA (aminoacids 1-415) was amplified using
primers LOX-F3 (59-GGGGGATCCCAATC TGGCAAAAG-
GAGTGATGC-39) and LOX-R3 (59-GGGCTCGAG-
GAAATTGTGCAGCC TGAGGCATA-39); LOX-PP cDNA
(aminoacids 1–179) was amplified using primers LOX-F3 and
LOX-R7 (59-GGGCTCGAGGTCAGAGTACTTG-
TAGGGGTTGTA-39); LOXenz cDNA (aminoacids 166–415)
was amplified using primers LOX-F7 (59-GGGGGATCCA-
GAAGTTCCTGCGCTCAGTAA-39) and LOX-R3. The ampli-
fied fragments were digested with BamHI and XhoI, cloned into
the pENTR2B plasmid (Invitrogen) and transferred by recombi-
nation to the lentiviral doxycycline-inducible plasmid pLenti4-
TO-V5-DEST (Invitrogen). Then, A673/TR Ewing sarcoma cells
expressing the tetracycline repressor [8,9] were infected with
lentiviruses containing the corresponding cDNAs. Control cells
were infected with empty lentiviral vector. Stable clones were
selected with zeocin (100 mg/ml). Induction of LOX, LOX-PP
and LOXenz were assayed by quantitative RT–PCR and/or
western-blots upon doxycycline (1 mg/ml) stimulation. Clones
displaying the highest levels of mRNA and/or protein expression
upon doxycycline stimulation were chosen for additional studies.
Multiplex real-time quantitative RT-PCR
Real-time PCR was performed to quantify steady state mRNA
levels as described elsewhere [13]. Sequences of the primers and
TaqMan probes used were as following: for EWS/FLI1, EWS/
FLI1-F, 59-AGCCAAGCTCCAAGTCAATATAG-39, EWS/
FLI1-R, 59 –TCCTCTTCTGACTGAGTCATAAG-39; and
EWS/FLI1 TaqMan probe, 59-TET-AACAGAGCAGCAGC-
TACGGGCAGCA-TAMRA-39; For LOX, we used a commer-
cially available TaqMan probe mix (Hs00942480_m1, Applied
Biosystems, Foster City, CA); for TATA-binding protein (TBP;
used as a reference gene), TBP-F, 59-GAACATCATGGATCA-
GAACAACAG-39, TBP-R, 59 ATTGGTGTTCTGAA-
TAGGCTGTG 39; and TBP TaqMan probe 59 FAM-
CTGCCACCTTACGCTCAGGGCTTGG-TAMRA 39.
Western Blot analysis
Whole cell extracts were obtained directly from cell layers lysed
in RIPA buffer (16 PBS, 0,1% SDS, 1% NP-40, 0,5% sodium
deoxycholate) supplemented with a protease and phosphatase
inhibitor cocktail (Roche). For immunoprecipitation of LOX-PP,
conditioned media was collected and concentrated 106 using a
10,000 molecular weight cut-off Amicon Ultra centrifugal filter
units (Millipore, Billerica, MA, USA). Then, 1.5 ml of concen-
trated media were cleared with 25 ml of protein A Sepharose (GE
Healthcare, Uppsala, Sweden) and supernatant incubated with
1 ml of anti-V5 overnight at 4uC with rocking. Next, 25 ml of
protein A Sepharose were added, incubated 1–4 hours at 4uC with
rocking and antigen-antibody complex precipitated by centrifu-
gation. The pelleted precipitates containing LOX bound proteins
were washed 3 times in PBS containing 0,5% Triton X-100 and
1 mM PMSF and directed resuspended in Laemli buffer. To
perform LOX-PP deglycosylation, immunoprecipitated LOX-PP
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was subjected to Peptide-N-Glycosidase F (PNGase F) treatment
according to manufacturer instructions (New England BioLabs,
Ipswich, MA). Treated and untreated samples were then
resuspended in Laemli buffer prior to gel electrophoresis.
Proteins were subjected to electrophoresis on 10 or 12% SDS-
polyacrylamide gel, blotted onto PVDF membranes (Pall, Port
Washington, NY, USA) and incubated with the corresponding
primary antibodies. After incubation with the secondary HRP-
conjugated antibody, membranes were subjected to enhanced
chemiluminescence (ECL, GE Healthcare) detection analysis. To
ensure equal loading of samples in each lane, membranes were
stripped and reprobed with an anti-tubulin monoclonal antibody.
Anti-FLI1 antibody (# 554267) was purchased from BD
Pharmingen (San Diego, CA, USA), anti-LOX (# L4794) and
anti-tubulin (# T9026) from Sigma-Aldrich, anti-V5 (# R960-25)
from Invitrogen, anti-P-Erk (P-Tyr 204, # sc-7383) from Santa
Cruz Biotechnology (Santa Cruz, CA, USA), anti-Akt (# 9272),
anti-P-Akt (P-Ser 473, # 9271) and anti-Erk (# 9102) from Cell
Signalling (Boston, MA, USA). Horseradish peroxidase-conjugat-
ed secondary antibodies were purchased from Santa Cruz
Biotechonology.
Cell proliferation assays
Cumulative population doubling was determined in cells grown
during 25 days in the absence or in the presence of doxycycline
(1 mg/ml) in 100 mm dishes. Before reached confluence, the cells
were trypsinized and counted to determine the number of cell
duplications. Cell proliferation was also quantified with the
CellTiter-Fluor assay (Promega, Madison, WI, USA). Briefly,
3.000 cells were seeded into 96-well plate and allowed to attach for
48 h. Then, cells were incubated in presence of stimulus for 5
days. Culture medium was replaced every 2–3 days with medium
containing the corresponding stimulus. At the end of the
experiment, CellTiter-Fluor reagent was added to each well and
incubated for 1 h at 37uC. Fluorescence was measured using an
Infinite M200 (Tecan, Männerdorf, Switzerland) microplate
reader. To analyse the effect of an exogenous source of LOX-
PP on cell proliferation, we used a standard MTT assay to
quantify viable cells (Promega). In these assays, A673 cells were
plated at a density of 5.000 cells/well in 96-well plates, incubated
during 72 hours with conditioned culture media and then treated
with MTT solution according to manufacturer’s instructions.
Conditioned culture media were obtained and prepared from
A673/TR/LOX-PP cells incubated in presence (LOX-PP rich
media) or in absence (control media) of doxycycline as described in
the previous section.
Colony formation assay
Cells were plated by triplicate (50,000 cells per 60 mm dishes) in
soft agar and cultured in presence or absence of doxycycline
during 25 days. Fresh culture medium was added to plates every
2–3 days. At the end of the experiment, three random fields for
each plate were photographed. The number of colonies for field
and its respective area were calculated using the image analysis
software ImageJ [59] (National Institute of Health, Bethesda, MD,
USA)
Cell migration assay
Cells were pre-treated with doxycycline for 24 hours to induce
the expression of the corresponding LOX proteins. Next, 300.000
pre-treated cells were suspended in 2 ml of medium containing
0.5% fetal bovine serum and placed in the upper compartment of
Transwells (8.0 mm pore size) (Corning Costar, Cambridge, MA,
USA). The lower compartment was filled with 3 ml of medium
containing 10% fetal bovine serum as chemoattractant. After 6 h
of incubation to allow cells to migrate through the membrane, the
cells remaining on the upper face of the membrane were removed
using a cotton wool swab, while the cells on the lower side of the
membrane were fixed with methanol and stained with crystal
violet. After washing with PBS, crystal violet was dissolved in PBS
with 2% SDS and absorbance quantified at 560 nm using an
Infinite M200 (Tecan) microplate reader.
Tumor formation assay in nude mice
Athymic 6-week-old female BALB/c nu/nu mice (Harlan
Ibérica, Barcelona, Spain) were used in these experiments, which
were all carried out in accordance with Institutional and European
Union guidelines. Cells were washed twice in PBS and
resuspended in Matrigel (BD Biosciences) diluted 1/10 in DMEM
at a density of 56107 cells/ml. Animals were subcutaneously
injected with the cell solution (0.1 ml) into the left flanks of the
mice. Animals were then kept under pathogen free conditions and
observed daily for any visible signs of tumors at the injection sites.
The tumor volume was measured every 2 or 3 days and calculated
using the formula L6W26p/6, where L is the length and W is the
width of the tumor. When indicated, doxycycline was given by oral
route in natural mineral water at a concentration of 1 mg/mL
Control animals received water alone. When tumor volume
reached 0,5 cm3, mice were sacrificed and tumors were removed.
Gene expression profiles and functional genomic
analyses
To identify genes and pathways regulated by LOX-PP in A673
cells, we used Agilent SurePrint G3 60K v2 microarrays. We
analysed the RNA isolated from three separate experiments
performed with A673/TR/empty (control cells) and A673/TR/
LOX-PP cells stimulated with doxycycline for 72 h to induce the
expression of LOX-PP. Labelling, hybridization and scanning
were performed at NIMGenetics (Madrid, Spain). Functional
genomic analysis was carried out using Gene Set Enrichment
Analyses (GSEA) (http://www.broadinstitute.org/gsea/index.jsp,
[42]. GSEA is a computational method that determines whether
an a priori defined set of genes (made for example by genes that
belong to a defined pathway or by genes that share a cis-regulatory
motif) is overrepresented at the top or bottom of a ranked list of
genes (in our case the list of genes differentially regulated by LOX-
PP, ranked using the Student’s t-test metric). Gene set permutation
was carried out to compute NES (Normalized Enrichment Score)
that reflects the degree to which a gene set is overrepresented at
the top or bottom of a ranked list of genes. We considered that a
gene set/pathway is significantly altered by LOX-PP if that gene
set reached a False Discovery Rate (FDR) bellow 0.5%
(FDR,0.005), which represent a very stringent FDR cut-off.
The FDR estimates the probability that a gene set with a given
NES represents a false positive finding.
Statistical analysis
For a single comparison of two groups, two tailed Student’s t test
was used. For all analyses, the level of significance was set at
P,0.05. All statistical calculations were made using the GraphPad
Prism statistical software version 4.0 (GraphPad Software, San
Diego, CA).
Supporting Information
Figure S1 Relative expression of LOX in human tumors.
(TIFF)
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Figure S2 Functional analysis of gene expression pro-
files deregulated by LOX-PP (GSEA analysis).
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